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Change of the EGFR expression and downstream signal pathway 
in A549 cell Treated with ZD1839
Xu, Chongrui; Guo, Ailin; Lin, Jiayin; Zhou, Qing; Wang, Zheng; 
Wang, Kun; Yang, Suqing; Wu, Yilong 
Guangdong Provincial People’s Hospital, Guangzhou, China
Object: Discuss the change of the EGFR expression and downstream 
signal pathway in A549 cell treated with ZD1839. 
Methods: The inhibition of the A549 cell treated with ZD1839 was 
measured by MTT assay and Real-Time PCR was used to evaluate the 
expression of EGFR and downstream signal pathway. 
Results: A549 cell was inhibited by ZD1839 in vitro. After treated 
with ZD1839, the expression of EGFR was 1.10 fold compared with 
the cell without ZD1839 and Ras gene was 1.09 fold. The expression 
of MAPK was 52.1 percent of the cell without ZD1839, PI3K was 16.4 
percent and Akt was 25.3 percent. ZD1839 didn’t affect the expression 
of EGFR and Ras in A549 cell but down regulated the expression of 
MAPK, PI3k and Akt. 
Conclusion: ZD1839 inhibited A549 cell by inhibiting the tyrosine 
kinase activity of EGFR and the PI3K/Akt, MAPK signal pathway.
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Expression and significance of RUNX3 in human lung cancer
Yanada, Masashi1 Shimada, Junichi1 Ito, Kazuhiro1 Terauchi, Kunihiko1 
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Background: Lung cancer is the leading cause of cancer related 
deaths throughout the world. A better understanding of the molecular 
pathogeneses of lung cancers is needed in order to achieve a preven-
tive or therapeutic breakthrough for reducing the number of deaths. 
Runt-related transcription factor 3 (RUNX3) has recently been shown 
to be down-regulated in human cancer tissues, including lung cancer. 
However, the clinical value of that ﬁnding is largely unknown. We in-
vestigated the associations of RUNX3 expression in lung cancer tissues 
with clinical characteristics and tumor recurrence.
Materials and Methods: The expression of RUNX3 in lung cancer 
cell lines was examined using a quantitative real-time reverse transcrip-
tase-polymerase chain reaction (RT-PCR) method. We also determined 
whether the expression of RUNX3 in the cell lines was associated with 
hemizygous deletion of the locus and methylation status in the exon 
1. Further, we investigated the methylation status of RUNX3 using a 
methylation speciﬁc PCR (MSP) technique and studied hemizygous 
deletion using bicolor ﬂuorescence in situ hybridization (FISH). In 
addition, primary lung tissues were obtained from Kyoto Prefectural 
University of Medicine, Japan. Among the 56 cases conﬁrmed as pri-
mary lung carcinomas, 40 were adenocarcinomas, 15 were squamous 
cell carcinomas, and 1 case was large cell carcinoma. The intratumoral 
expression level of RUNX3 mRNA was determined and compared with 
that in adjacent non-tumorous lung tissue using quantitative real-time 
RT-PCR in the 56 cases of non-small cell lung cancer. From those 
results, the relationship between the expression level of RUNX3 and 
clinicopathological factors was examined.
Results: RUNX3 gene expression was reduced or disappeared in all 
cell lines examined (P < 0.001). Eight of 15 lung cancer cell lines 
revealed methylated bands of RUNX3, whereas 7 showed unmethyl-
ated bands. Further, hemizygous deletion of RUNX3 was observed in 
8 of the cell lines by bicolor FISH. RUNX3/GAPDH mRNA levels 
were signiﬁcantly different between tumor tissues from the lung cancer 
specimens and adjacent non-malignant lung tissues (P < 0.001). No 
signiﬁcant differences in RUNX3/GAPDH mRNA levels were found 
related to age, gender, lymph node metastasis or tumor recurrence in 
the non-small cell lung cancer cases.
Conclusions: The present clinical and experimental data suggest 
that the comprehensive study of RUNX3 using quantitative real-time 
RT-PCR, MSP, and FISH would be beneﬁcial for understanding the 
pathogenetic mechanisms of human lung cancer at the molecular level.
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Growth regulation via insulin-like growth factor binding protein-4 
and -2 in lung epithelial cells and cancers
Yazawa, Takuya1 Sato, Hanako2 Shimoyamada, Hiroaki1 Okudela, Koji1 
Kitamura, Hitoshi1 
1 Dept. of Pathobiology, Yokohama City University Graduate School of 
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Gain-of-function point mutation in K-ras affect early events in pulmo-
nary bronchioloalveolar carcinoma and continuous K-Ras activation 
accelerates growth of lung epithelial cells. We investigated altered 
mRNA expression on K-Ras activation in human lung epithelial cells 
and found that two kinds of growth-modulating molecules, insulin-
like growth factor binding protein (IGFBP)-4 and -2 was signiﬁcantly 
upregulated by mutated K-ras transgene. Lung cancer cell growth was 
also accelerated by mutated K-ras gene transduction, whereas IGFBP-
4/-2 induction was weaker compared with mutated K-Ras-expressing 
lung epithelial cells. To understand the differences in IGFBP-4/-2 
inducibility via K-Ras-activated signaling between nonneoplastic 
lung epithelia and lung carcinoma, we addressed the mechanisms of 
IGFBP-4/-2 transcriptional activation. Our results revealed that Egr-1, 
which is induced on activation of Ras-MAPK signaling, is crucial for 
transactivation of IGFBP-4/-2. Furthermore, IGFBP-4 and IGFBP-2 
promoters were often hypermethylated in lung carcinoma, yielding low 
basal expression/weak induction of IGFBP-4/-2. These ﬁndings suggest 
that continuous K-Ras activation accelerates cell growth and evokes 
a feedback system through IGFBP-4/-2 to prevent excessive growth. 
Moreover, this growth regulation is disrupted in lung cancers because 
of promoter hypermethylation of IGFBP-4/-2 genes.
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Identification of novel tumor suppressor gene candidates in small 
cell lung cancer for use in cancer gene therapy
Zandi, Roza1 Willumsen, Berthe M.2 Pedersen, Nina1 Poulsen, Hans S.1 
1 Department of Radiation Biology Section 6321, Copenhagen National 
University Hospital, Copenhagen, Denmark 2 Department of Molecular 
Biology, University of Copenhagen, Copenhagen, Denmark 
Small cell lung cancer (SCLC) is a deadly disease with no current 
satisfactory treatments. There is thus an urgent need for development of 
more efﬁcient treatment modalities for patients with this cancer form. 
One intriguing modality is cancer gene therapy and one the most com-
mon approaches is tumor suppressor restoration therapy. In tumor sup-
pressor restoration therapy a wild-type tumor suppressor gene (TSG) is 
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introduced into cancer cells, in which the gene is inactivated, to restore 
the cell’s normal gene functions. Such introduction of TSGs in the 
cancer cells generally induces apoptosis and/or cell cycle arrest. Gene 
therapy using various known and newly identiﬁed TSGs as therapeutic 
genes have reached clinical trials for treatment of several cancer types. 
However, as different types of cancers have different tumor suppressor 
deﬁciencies, the strategy must be customized to each type. Thus, the 
aim of this study is to identify and characterize novel TSG candidate(s) 
speciﬁc SCLC, which eventually can be tested for use in cancer gene 
therapy. 
By a global gene expression analysis (Affymetrix) on a large panel 
of SCLC cell lines, corresponding tumor xenografts, and transformed 
mouse cell lines, we have identiﬁed four genes, whose expression is 
markedly downregulated in cancer and transformed mouse cell lines 
compared to normal cells and tissues. This was further veriﬁed by 
semi-quantitative RT-PCR. To determine whether they posses tumor 
suppressing activity we are currently investigating the effect of overex-
pression of each of these genes on cell proliferation, migration and cell 
cycle arrest by transiently transfecting selected SCLC and transformed 
mouse cell lines. If any demonstrate tumor suppressive activity, they 
will be chosen as potential candidates for the development of gene 
therapy for patients with SCLC.
An update will be presented.
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STI-571 inhibits the growth of non-small cell lung cancer cell and 
intensifies the cisplatin effect in vitro
Zhou, Caicun; Su, Chumxia; Su, Bu; Zhao, Yingmin 
Dept. Medical Oncology, Shanghai Pulmonary Hospital, Tongji Univer-
sity, Shanghai, China
Background: STI571 Gleevec, Imatinib(c) is the ﬁrst cancer -related 
signal transduction inhibitor which selectively suppresses the activity 
of c-KIT, ABL and platelet-derived growth factor receptor(PDGFR). 
Methods: We conducted MTT assay to explore the growth inhibitory 
effect of STI571 alone or with cisplatin on lung cancer cells, cell cycle 
analysis to conﬁrm the cell distribution, immunocytochemistry to test 
the expression of PDGFRs, c-KIT in the non-small cell lung cancer cell 
lines immunohistochemistry to investigate the expression of PDGFRs 
and c-KIT. 
Results: A549-resistant cell lines showed marked inhibition of cell 
growth after treatment with STI571 and combination with cisplatin,but 
not A549-sensetive cells. Cell cycle analysised by ﬂow cytometry 
revealed that STI571 treatment increased the fraction of A549-resistant 
cells in S and G2/M phases,respectively,indicating induction of S and 
G2/M transition arrest.A549 cell lines highly express PDGFRs, A549-
resistant cell lines also express c-KIT.
Conclusion: These results provide a potential therapeutic selection for 
non-small cell lung cancer. STI571 as a single agent or in combination 
with cisplatin is a potential new targeted strategy.
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Effects of collagen IV on cisplatin-induced apoptosis of non-small 
cell lung cancer cells
Zhou, Caicun1 Su, Chunxia2 Su, Bo2 
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University, Shanghai, China 2 Shanghai Pulmonary Hospital, Tongji 
University, Shanghai, China 
Background and Objectives: Most lung cancer patients cannot be 
cured with current therapeutic modalities. Drug resistance is one of 
the major causes in treatment failure of non-small cell lung cancer 
{NSCLC). Classical drug resistant mechanisms have been elucidated 
upon monocellular models. However, these models do not consider the 
tumor microenvironment in vivo. Recently, interactions between the tu-
mor cells and extracellular matrix (ECM) have been shown to be one of 
the mechanisms of drug resistance. We investigated effects of ECM on 
cisplatin-induced apoptosis of the cell line A549 and cisplatin-resistant 
cell line A549-DDP, and the role of phosphatidylinositol 3’-kinase(PI3-
K) in ECM’s signal pathway. 
Methods: A549 and A549-DDP cells were cultured in RPMI 1640 
supplemented with 10% fetal calf serum in vitro, 6 µmol/L cisplatin 
(DDP )was added to maintain the drug resistant phenotype of the A549-
DDPcells. The inhibitory effects of DDP and/or LY294002 (PI3-K 
inhibitor) on cellular proliferation were tested by methabenzthiazuron 
(MTT) assay. Immunocytochemistry was used to detect the expression 
of extracellular matrix and integrin β1 of these two cell lines, respec-
tively. Cell adhesion experiments were used to test cell adhesion rates. 
Flow cytometry was applied to study the inﬂuence of collegen IV (C 
IV) and LY294002 on A549/DDP cells’ apoptosis and cell cycle distri-
bution before and after DDP treatment. 
Results: The expression of ECM proteins in cisplatin-sensitive and cis-
platin-resistance lung cancer cells were different. Extracellular matrix 
Cmediated cell adhesion promotes survival of A549 and A549-DDP 
cells from cisplatin insults. Pre-coating with collagen IV protect non-
small cell lung cancer cells from drug-induced growth inhibition, which 
is PI 3-kinase/Akt-dependent. Combining cisplatin with LY294002 
caused greater increases in apoptosis compared with that caused by the 
inhibitor or cisplatin alone. Collagen IV changed A549 cells cell cycle 
distribution, with an increase in G1 phase, a reduction in S and G2/M 
phases, as treated with cisplatin or combined with LY294002. After be-
ing infected with dominant-negative forms of integrin β1 plasmid, both 
of these two cell lines can become relatively sensitive to cisplatin. 
Conclusions: ECM may provide protection against cisplatin-induced 
apoptosis of A549 and A549-DDP cells, while LY294002 increases 
the growth inhibitory effect of cisplatin. Integrin &β1 signaling and 
PI3-Kinase pathway may be important survival pathways of drug-in-
duced apoptosis in lung cancer cells and activation of this pathway may 
contribute to the generation of drug resistance.
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A genomic in vitro model of ribonucleotide reductase M1 (RRM1) 
expression modulation for efficacy assessment of multidrug 
therapy
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